Barinthus Biotherapeutics PLC Sponsored ADR (BRNS)
(Delayed Data from NSDQ)
$1.51 USD
+0.04 (2.72%)
Updated Jul 12, 2024 03:59 PM ET
After-Market: $1.47 -0.04 (-2.65%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BRNS 1.51 +0.04(2.72%)
Will BRNS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BRNS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BRNS
Synlogic, Inc. (SYBX) Reports Q4 Loss, Tops Revenue Estimates
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
BRNS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates
The Joint Corp. (JYNT) Q4 Earnings and Revenues Top Estimates
Other News for BRNS
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and Barinthus Biotherapeutics (BRNS)
Barinthus Biotherapeutics price target lowered by $3 at H.C. Wainwright, here's why
Barinthus Biotherapeutics price target lowered by $4 at Barclays, here's why
Barinthus Bio cuts 25% of staff amid pipeline shakeup